

Real world utilization and effectiveness of remote electrical neuromodulation in treatment of migraine in India

Deepak Arjundas¹, Akshay Deepak², Tamanna Deepak Rattha¹

¹Mercury hospital, Vijaya health center & Vijaya hospital, Chennai, India; ²Mercury hospital, Vijaya health center & Vijaya hospital, Kauvery hospital, Chennai, India

Nerivio, is a Remote electrical neuromodulation device, cleared by CDSCO for acute and/ or preventive treatment of migraine with or without aura for patients aged 12+ years in India. It is applied on the upper arm for 45 minutes every other day for prevention of migraine or SoS for abortive treatment.

There is limited real world experience reported from India and this study highlights the real world utilization and patient reported efficacy outcomes with Nerivio in India.




Method: Patients ≥ 12 years old, diagnosed with migraine according to ICHD-3 criteria, using Nerivio for preventive treatment of migraine between Sept 2024 to April 2025 were included in the study.


At the end of each REN device usage, patient feedback data were collected over a phone call. De identified patient data was collected from the Portea Medical patient support program for analysis.

Result: 129 patients used Nerivio for prevention of migraine. Of these, 78% (n=101) patients were between the age group of 21-50 years. ~3 out of 4 patients were female and majority were non-working and had chronic migraine (72%).


Number of patients using Nerivio across different age groups



83/ 129 patients used single device only whereas 46 patients used ≥ 2 devices. In total, patients used 1,759 sessions and used an average intensity of 45.23% (75% sessions were between 20%- 60% intensity) and average duration of 44.4 minutes.



Efficacy of Nerivio based on number of devices used by patients (n=92)



2 out of 3 patients reported relief in their migraine (n=92/ 129). 38/129 patients provided feedback regarding reduction of headache days and pain intensity. 29/38 patients had > 14 headache days before using Nerivio, 25/ 29 patients reported reduction in headache days.

Conclusion: Nerivio was safe and effective. Using Nerivio resulted in reduction of headache days and pain intensity. Greater percentage of patients report relief with their migraines when they used ≥ 2 devices.